<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01999101</url>
  </required_header>
  <id_info>
    <org_study_id>PHS-Px-104-II-01</org_study_id>
    <nct_id>NCT01999101</nct_id>
  </id_info>
  <brief_title>Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients</brief_title>
  <official_title>A Safety Pilot Study of Px-104 in Non-alcoholic Fatty Liver Disease (NAFLD) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phenex Pharmaceuticals AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Phenex Pharmaceuticals AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the study is to evaluate the safety and tolerability of Px-104 in NAFLD
      patients and to assess the influence of Px-104 on hepatic fat.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>28 days</time_frame>
    <description>Analysis of clinical chemistry, hematology, and assessment of clinical signs and adverse events over 28 days. Change day 28 vs. day 1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of hepatocellular lipid content</measure>
    <time_frame>day 1 and day 28</time_frame>
    <description>Measurement of hepatic fat (%) by Magnetic resonance spectroscopy (MRS), change day 28 vs. day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in oral glucose tolerance test (oGTT)</measure>
    <time_frame>baseline and day 27</time_frame>
    <description>Measurement of plasma glucose level (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fibroblast growth factor 19 (FGF-19)</measure>
    <time_frame>days 1, 7, 14, 21 and 28</time_frame>
    <description>Measurement by ELISA (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma bile acid concentration</measure>
    <time_frame>days 1, 7, 14, 21, and 28.</time_frame>
    <description>Assessment by LC-MS/MS (µmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Px-104 and conjugates</measure>
    <time_frame>day 1 and day 28</time_frame>
    <description>Measurement by LC-MS/MS (ng/mL). AUC, Cmax and other pk parameters</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in the Saccharose-Lactulose-Mannitol + Sucralose (SLM+S) Test to evaluate the intestinal permeability</measure>
    <time_frame>baseline and day 27</time_frame>
    <description>Measurement of urinary concentrations of Saccharose, Lactulose, Mannitol and Sucralose by HPLC</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of liver steatosis by CAP-Fibroscan</measure>
    <time_frame>baseline and day 28</time_frame>
    <description>Measurement of hepatic fat (%) by CAP-Fibroscan</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Non Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Px-104</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Px-104 capsules, 5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Px-104</intervention_name>
    <description>28 days treatment</description>
    <arm_group_label>Px-104</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NAFLD patients

          -  Weight &gt; 65 kg

          -  BMI &gt; 25 and &lt; 40

          -  Negative blood or urine pregnancy test (for females of childbearing potential)
             collected at screening followed by another negative serum pregnancy test collected
             within 24 hours prior to the first dose of study drug.

          -  Contraception: Female patients must be postmenopausal, surgically sterile, or if
             premenopausal, must be prepared to use at least two effective (≤1% failure rate)
             method of contraception during the course of the study and for 14 days after the end
             of dosing. Male patients with female partners of child bearing potential must be
             prepared to use at least two effective methods of contraception with all sexual
             partners unless they have had a prior vasectomy

          -  Must be willing and able to give written informed consent and agree to comply with the
             study protocol.

          -  Sinus rhythm in 12-lead ECG

        Exclusion Criteria:

          -  Evidence of excessive alcohol, drug or substance abuse (excluding marijuana use)
             within 1 year of first dose.

          -  History or other evidence of a medical condition associated with chronic liver disease
             other than.

          -  History or other evidence of decompensated liver disease (Child-Pugh Grade B or
             higher), coagulopathy, hyperbilirubinemia, hepatic encephalopathy, hypoalbuminemia,
             ascites, hepatic encephalopathy, and bleeding from esophageal varices are conditions
             consistent with decompensated liver disease.

          -  Concomitant intake of fibrates or statins (at least 4-6 weeks before start;
             considering half life of medication).

          -  Any clinically relevant findings in ECG (identified via 24h-Holter ECG or 12-Lead ECG)
             at screening

          -  History of any structural cardiac disease.

          -  In addition, patients with documented or presumed unstable coronary artery disease,
             stable or unstable cardiovascular disease or cerebrovascular disease.

          -  One or more of the following conditions: (1) poorly controlled hypertension, OR (2)
             screening or baseline blood pressure ≥ 160 mmHg for systolic OR (3) screening or
             baseline blood pressure ≥ 100 mmHg for diastolic blood pressure.

          -  Type I or II diabetes with HbA1C &gt; 6.5% at screening and/or fasting plasma glucose &gt;
             7mmol/L (&gt; 126 mg/dl).

          -  History or other evidence of a clinically relevant ophthalmologic disorder due to
             diabetes mellitus or hypertension or history or other evidence of severe retinopathy
             (e.g., cytomegalovirus, macular degeneration).

          -  Known sensibility to any ingredients contained in the investigational medicinal
             product (IMP)

          -  All conditions that do not allow magentic resonance (MR) assessments

          -  History of having received any investigational drug ≤ 3 months and/or 6 x half-life
             prior to the first dose of study drug or the expectation that such drugs will be used
             during the study. Patients enrolled in this study cannot be enrolled in another study
             for either research, diagnostic or treatment purposes.

          -  Woman with childbearing potential unless using adequate contraception (see inclusion
             criteria); females who are pregnant or breast feeding.

          -  History of severe allergic

          -  Evidence of an active or suspected cancer, or a history of malignancy within the last
             2 years, with the exception of patients with basal cell carcinoma that has been
             excised and cured.

          -  History of any systemic anti-neoplastic or immunomodulatory treatment (including
             supraphysiologic doses of steroids and radiation) 6 months prior to the first dose of
             study drug or the expectation that such treatment will be needed at any time during
             the study.

          -  History of bleeding disorders or anticoagulant use

          -  History or other evidence of chronic pulmonary disease associated with functional
             limitation.

          -  History of uncontrolled severe seizure disorder.

          -  Poorly controlled thyroid dysfunction.

          -  History of major organ transplantation with an existing functional graft.

          -  Any signs of acute infection or inflammation

          -  History or other evidence of severe illness, or any other conditions which would make
             the patient, in the opinion of the investigator, unsuitable for the study.

          -  Any herbal supplements containing silymarin, tocopherol, vitamin C, riboflavins,
             proflavins, curcumin. (at least 4-6 months before the study)

          -  Positive test at screening for anti-Hepatits A virus (HAV) Immunoglobulin M (IgM),
             Hebatitis B surface antigen (HBsAg), Anti-Hepatits B core Antigen Immunglobulin M
             antibody (anti-HBc IgM Ab), or anti-HIV Ab.

          -  Subjects who have undergone surgery within the last 3 months.

          -  Subjects who have had a prior gastrointestinal surgery.

          -  Subjects who will be unavailable for the duration of the trial, who are unlikely to be
             compliant with the protocol, or who are felt to b unsuitable by the investigator for
             any other reason

          -  Imprisonment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Trauner, Professor Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Gastroenterology and Hepatology, Department of Internal Medicine III</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <last_update_submitted>September 28, 2016</last_update_submitted>
  <last_update_submitted_qc>September 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

